In a nutshell, nano-delivery of AMPs has been proven to be an effective strategy to overcome the shortcomings of antimicrobial peptides, such as physiological instability and systemic toxicity, resulting in improved biosafety and efficacy against bacterial infections and sepsis both in vitro and in vivo. This evidence concerns the gene ADSL and bacterial infectious disease.